A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
Status:
Not yet recruiting
Trial end date:
2024-08-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the tolerability and side effects related to
LY3875383 given as a single injection under the skin to healthy participants and participants
with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets
into the blood stream and how long the body takes to get rid of it. Each enrolled participant
will receive a single dose of either LY3875383 or placebo.The study will be conducted in four
parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.